• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对委内瑞拉马脑炎病毒疫苗载体表达的1型人类免疫缺陷病毒免疫原的体液免疫、黏膜免疫和细胞免疫。

Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

作者信息

Caley I J, Betts M R, Irlbeck D M, Davis N L, Swanstrom R, Frelinger J A, Johnston R E

机构信息

Department of Microbiology, School of Medicine, University of North Carolina, Chapel Hill 27599, USA.

出版信息

J Virol. 1997 Apr;71(4):3031-8. doi: 10.1128/JVI.71.4.3031-3038.1997.

DOI:10.1128/JVI.71.4.3031-3038.1997
PMID:9060663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC191432/
Abstract

A molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE) has been genetically configured as a replication-competent vaccine vector for the expression of heterologous viral proteins (N. L. Davis, K. W. Brown, and R. E. Johnston, J. Virol. 70:3781-3787, 1996). The matrix/capsid (MA/CA) coding domain of human immunodeficiency virus type 1 (HIV-1) was cloned into the VEE vector to determine the ability of a VEE vector to stimulate an anti-HIV immune response in mice. The VEE-MA/CA vector replicated rapidly in the cytoplasm of baby hamster kidney (BHK) cells and expressed large quantities of antigenically identifiable MA/CA protein. When injected subcutaneously into BALB/c mice, the vector invaded and replicated in the draining lymphoid tissues, expressing HIV-1 MA/CA at a site of potent immune activity. Anti-MA/CA immunoglobulin G (IgG) and IgA antibodies were present in serum of all immunized mice, and titers increased after a second booster inoculation. IgA antibodies specific for MA/CA were detected in vaginal washes of mice that received two subcutaneous immunizations. Cytotoxic T-lymphocyte responses specific for MA/CA were detected following immunization with the MA/CA-expressing VEE vector. These findings demonstrate the ability of a VEE-based vaccine vector system to stimulate a comprehensive humoral and cellular immune response. The multifaceted nature of this response makes VEE an attractive vaccine for immunization against virus infections such as HIV-1, for which the correlates of protective immunity remain unclear, but may include multiple components of the immune system.

摘要

委内瑞拉马脑炎病毒(VEE)的一种分子克隆减毒株已被基因构建为一种具有复制能力的疫苗载体,用于表达异源病毒蛋白(N. L. 戴维斯、K. W. 布朗和R. E. 约翰斯顿,《病毒学杂志》70:3781 - 3787,1996年)。将1型人类免疫缺陷病毒(HIV - 1)的基质/衣壳(MA/CA)编码结构域克隆到VEE载体中,以确定VEE载体刺激小鼠抗HIV免疫反应的能力。VEE - MA/CA载体在幼仓鼠肾(BHK)细胞的细胞质中快速复制,并表达大量抗原可识别的MA/CA蛋白。当皮下注射到BALB/c小鼠体内时,该载体侵入引流淋巴组织并在其中复制,在具有强大免疫活性的部位表达HIV - 1 MA/CA。所有免疫小鼠的血清中均存在抗MA/CA免疫球蛋白G(IgG)和IgA抗体,第二次加强接种后抗体滴度升高。在接受两次皮下免疫的小鼠的阴道灌洗液中检测到了对MA/CA特异的IgA抗体。在用表达MA/CA的VEE载体免疫后,检测到了对MA/CA特异的细胞毒性T淋巴细胞反应。这些发现证明了基于VEE的疫苗载体系统刺激全面的体液和细胞免疫反应的能力。这种反应的多方面性质使VEE成为一种有吸引力的疫苗,可用于针对如HIV - 1等病毒感染进行免疫接种,对于HIV - 1,保护性免疫的相关因素仍不清楚,但可能包括免疫系统的多个成分。

相似文献

1
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.针对委内瑞拉马脑炎病毒疫苗载体表达的1型人类免疫缺陷病毒免疫原的体液免疫、黏膜免疫和细胞免疫。
J Virol. 1997 Apr;71(4):3031-8. doi: 10.1128/JVI.71.4.3031-3038.1997.
2
Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy.表达HIV-1蛋白的委内瑞拉马脑炎病毒载体:提高疫苗效力的载体设计策略
Vaccine. 1999 Aug 6;17(23-24):3124-35. doi: 10.1016/s0264-410x(99)00142-5.
3
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.来自减毒委内瑞拉马脑炎病毒的复制子辅助系统:异源基因的体外表达及体内针对异源病原体的免疫接种
Virology. 1997 Dec 22;239(2):389-401. doi: 10.1006/viro.1997.8878.
4
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.一种在淋巴结中表达外源基因并能抵御黏膜攻击的病毒疫苗载体。
J Virol. 1996 Jun;70(6):3781-7. doi: 10.1128/JVI.70.6.3781-3787.1996.
5
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.用甲病毒复制子颗粒进行保护性黏膜免疫后,人免疫缺陷病毒Gag特异性表达γ干扰素细胞的特性分析
J Virol. 2005 Jun;79(11):7135-45. doi: 10.1128/JVI.79.11.7135-7145.2005.
6
Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.快速抗原降解和委内瑞拉马脑炎病毒糖蛋白特异性对委内瑞拉马脑炎病毒复制子疫苗诱导的免疫反应的影响。
Virology. 2008 Jan 5;370(1):22-32. doi: 10.1016/j.virol.2007.08.020. Epub 2007 Sep 27.
7
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.一种源自委内瑞拉马脑炎病毒和辛德毕斯病毒的甲病毒复制子颗粒嵌合体是一种高效的基因疫苗递送载体。
J Virol. 2003 Oct;77(19):10394-403. doi: 10.1128/jvi.77.19.10394-10403.2003.
8
Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.黏膜佐剂增强的重组流感病毒载体疫苗在小鼠中诱导针对 HIV-1 的 T 细胞和抗体应答。
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00059-21.
9
Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate.用一种减毒活委内瑞拉马脑炎病毒候选疫苗进行肠胃外免疫诱导的黏膜免疫。
Virology. 1997 Feb 17;228(2):153-60. doi: 10.1006/viro.1996.8381.
10
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.用表达诺如病毒样颗粒的委内瑞拉马脑炎复制子接种小鼠后的全身、黏膜和异型免疫诱导
J Virol. 2002 Jan;76(2):730-42. doi: 10.1128/jvi.76.2.730-742.2002.

引用本文的文献

1
Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.在前列腺癌的HLA-DR转基因小鼠模型中,表达前列腺特异性抗原的基于甲病毒的病毒样颗粒载体的抗肿瘤作用。
Vaccine. 2015 Oct 5;33(41):5386-5395. doi: 10.1016/j.vaccine.2015.08.062. Epub 2015 Aug 28.
2
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.基于蛋白质抗原的鼻内和口服疫苗接种:优势、挑战与制剂策略
Protein Cell. 2015 Jul;6(7):480-503. doi: 10.1007/s13238-015-0164-2. Epub 2015 May 6.
3
Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges.用于新生儿的呼吸道病毒病原体疫苗:机遇与挑战
J Immunol. 2014 Dec 1;193(11):5363-9. doi: 10.4049/jimmunol.1401410.
4
RNA-based drugs and vaccines.基于RNA的药物和疫苗。
Expert Rev Vaccines. 2015 Feb;14(2):253-63. doi: 10.1586/14760584.2015.959932. Epub 2014 Sep 14.
5
The influence of delivery vectors on HIV vaccine efficacy.不同载体对 HIV 疫苗效力的影响。
Front Microbiol. 2014 Aug 22;5:439. doi: 10.3389/fmicb.2014.00439. eCollection 2014.
6
Alphavirus-based vaccines.基于甲病毒的疫苗。
Viruses. 2014 Jun 16;6(6):2392-415. doi: 10.3390/v6062392.
7
Bioluminescent imaging and histopathologic characterization of WEEV neuroinvasion in outbred CD-1 mice.在远交 CD-1 小鼠中观察 WEEV 神经入侵的生物发光成像和组织病理学特征。
PLoS One. 2013;8(1):e53462. doi: 10.1371/journal.pone.0053462. Epub 2013 Jan 2.
8
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.委内瑞拉马脑炎病毒复制子颗粒共递送抗原和 IL-12 增强了抗原特异性免疫应答和抗肿瘤作用。
Cancer Immunol Immunother. 2012 Nov;61(11):1941-51. doi: 10.1007/s00262-012-1248-y. Epub 2012 Apr 10.
9
A novel self-replicating chimeric lentivirus-like particle.一种新型的自我复制嵌合慢病毒样颗粒。
J Virol. 2012 Jan;86(1):246-61. doi: 10.1128/JVI.05191-11. Epub 2011 Oct 19.
10
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.呼吸道合胞病毒疫苗研发的生物学挑战和技术机遇。
Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x.

本文引用的文献

1
Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques.猕猴中通过靶向髂淋巴结免疫亚单位猴免疫缺陷病毒包膜和核心疫苗引发的保护性黏膜免疫。
Nat Med. 1996 Jul;2(7):767-75. doi: 10.1038/nm0796-767.
2
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.一种在淋巴结中表达外源基因并能抵御黏膜攻击的病毒疫苗载体。
J Virol. 1996 Jun;70(6):3781-7. doi: 10.1128/JVI.70.6.3781-3787.1996.
3
Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.从感染了表达1型人类免疫缺陷病毒(HIV-1)Gag的脊髓灰质炎病毒复制子的细胞中释放病毒样颗粒。
J Virol. 1996 Apr;70(4):2643-9. doi: 10.1128/JVI.70.4.2643-2649.1996.
4
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.重组塞姆利基森林病毒gp160疫苗和gp120亚单位疫苗对致死性猴免疫缺陷病毒SIVsmmPBj14疾病的保护作用。
J Virol. 1996 Mar;70(3):1953-60. doi: 10.1128/JVI.70.3.1953-1960.1996.
5
Toward an understanding of the correlates of protective immunity to HIV infection.迈向对HIV感染保护性免疫相关因素的理解。
Science. 1996 Jan 19;271(5247):324-8. doi: 10.1126/science.271.5247.324.
6
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.人类免疫缺陷病毒1型的不同分支间及分支内中和作用:基因分支并不对应中和血清型,但部分对应gp120抗原血清型。
J Virol. 1996 Jan;70(1):427-44. doi: 10.1128/JVI.70.1.427-444.1996.
7
Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.用重组p17/p24:Ty病毒样颗粒对人类HIV血清阴性志愿者进行免疫接种可引发HIV-1 p24特异性细胞免疫和体液免疫反应。
AIDS. 1993 Oct;7(10):1315-23.
8
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.1型人类免疫缺陷病毒原发性综合征中细胞免疫反应与病毒血症初始控制的时间关联。
J Virol. 1994 Jul;68(7):4650-5. doi: 10.1128/JVI.68.7.4650-4655.1994.
9
A strategy for prophylactic vaccination against HIV.一种针对艾滋病毒的预防性疫苗接种策略。
Science. 1993 May 28;260(5112):1270-2. doi: 10.1126/science.8098553.
10
The alphaviruses: gene expression, replication, and evolution.甲病毒属:基因表达、复制与进化
Microbiol Rev. 1994 Sep;58(3):491-562. doi: 10.1128/mr.58.3.491-562.1994.